Overall survival at 4 years of follow-up in a phase III trial of nivolumab plus ipilimumab combination therapy in advanced melanoma (CheckMate 067)

Overall survival at 4 years of follow-up in a phase III trial of nivolumab plus ipilimumab combination therapy in advanced melanoma (CheckMate 067)

Saved in:
Bibliographic Details
Published in:Annals of oncology Vol. 29; p. viii735
Main Authors: Hodi, F.S., Chiarion-Sileni, V., Gonzalez, R., Grob, J.J., Rutkowski, P., Cowey, C.L., Lao, C., Schadendorf, D., Wagstaff, J., Dummer, R., Ferrucci, P.F., Smylie, M., Hill, A.G., Hogg, D., Marquez-Rodas, I., Jiang, J., Rizzo, J., Larkin, J., Wolchok, J.
Format: Journal Article
Language:English
Published: England Elsevier Ltd 01-10-2018
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
ISSN:0923-7534
1569-8041
DOI:10.1093/annonc/mdy424.054